Skip to main content

Table 3 Intraoperative, histopathologic, and postoperative data of 188 patients with high-risk localized and locally advanced prostate cancer undergoing RARP

From: Robot-assisted radical prostatectomy in the treatment of patients with clinically high-risk localized and locally advanced prostate cancer: single surgeons functional and oncologic outcomes

Parameters N = 188
Operative time, median (IQR), minutes 185 (130–260)
Blood loss, median (IQR), ml 200 (150–450)
Blood transfusion 1 (0.5%)
PLND  
 Extended PLND 170 (90.4%)
 Limited PLND 18 (9.6%)
 Nodal involvement 12 (6.4%)
Complications  
 Clavien grade I, II 22 (11.7%)
 Clavien grade ≥ III 5 (2.7%)
Pathologic stage  
 High-risk localized (≤ pT2c) 63 (33.5%)
 High-risk locally advanced 125 (66.5%)
  pT3a 75 (39.9%)
  ≥ pT3b 50 (26.6%)
Pathologic Gleason score  
 7 81 (43.1%)
 8 74 (39.4%)
  ≥ 9 33 (17.6%)
PSMs  
 Overall 50 (26.6%)
 In pT2 cancer 16 (8.5%)
 In pT3 cancer 34 (18.1%)
Adjuvant treatment  
 Overall 63 (33.5%)
 Radiotherapy 25 (13.3%)
 Hormonal therapy 38 (20.2%)
Salvage treatment  
 Overall 35 (18.6%)
 Radiotherapy 10 (5.3%)
 Hormonal therapy 15 (8.0%)
 Secondary after adjuvant therapy 10 (5.3%)
Follow-up duration, median (IQR), month 66.5 (13–94)
 BCR 42 (22.3%)
 Time to BCR, median (IQR) 10.5 (3.5–26)